PVCTOTCPharmaceutical PreparationsFiscal year ends December 31

PROVECTUS BIOPHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.05+0.00 (+0.39%)

Close on Oct 19, 2026

Market cap: $20.55M
P/E (TTM): –
Dividend yield: –

PROVECTUS BIOPHARMACEUTICALS, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	0.34	0.62	0.56	0.99	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–	–
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Gross Profit	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Research & Development	1.90	2.05	1.75	2.39	2.61	2.81	4.00	4.75	8.20	8.21	11	5.81	3.60	5.01	8.81	8.42	4.91	–	–	–
General & Administrative	3.73	3.10	1.71	2.03	2.06	2.15	2.30	3.31	5.12	16	13	11	8.76	8.66	12	12	6.75	–	–	–
Operating Expenses	5.63	5.15	3.46	4.42	4.67	4.96	6.30	8.05	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-5.29	-4.53	-2.90	-3.43	-4.67	-4.96	-6.30	-8.05	-13	-25	-25	-13	-13	-14	-21	-21	-12	–	–	–
Interest Expense	0.01	0.01	0.01	0.00	0.96	1.75	1.46	0.97	–	–	–	–	–	–	0	–	–	–	–	–
Interest & Investment Income	–	–	–	–	0.00	0.00	0.02	0.02	0.03	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	–	–	–
Other Non-Operating Income	-0.21	-0.23	-0.20	-0.13	-0.87	-1.71	-0.62	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	0.68	0.83	0.17	–	–	4.18	–	–	–	–	–	–	–	–
Pretax Income	-5.51	-4.77	-3.10	-3.55	-5.54	-6.68	-6.92	-8.15	-14	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-5.51	-4.76	-3.10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	-0.07	-0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-5.43	-4.73	-3.10	-3.55	-5.54	-6.68	-6.92	-8.15	-14	-24	-25	-10	-28	-13	-19	-19	-12	-10	-10	-8.87
Preferred Dividends	–	–	–	–	–	–	–	–	–	2.05	–	0	1.19	0.18	0.25	10	–	–	–	–
Net Income to Common	–	–	–	–	–	–	–	-8.15	-14	-29	-25	-10	-29	-13	-20	-29	-12	–	–	–
EPS (Basic)(per share)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02	-0.04	-0.12	-0.13	-0.06	-0.22	-0.11	–	–	–	–	–	–
EPS (Diluted)(per share)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02	-0.04	-0.12	-0.13	-0.06	-0.22	-0.11	–	–	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	420	420	420	419	408	393	387	382	369	234	196	176	132	113	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	420	420	420	419	408	393	387	382	369	234	196	176	132	113	–	–	–	–	–	–
Net Interest Income	-0.21	-0.24	-0.22	-0.16	-0.96	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -1363.5%
Net margin: -1413.0%
Return on equity, FY2025: 88.6%

Financial strength

Current ratio: 0.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 15.0%

Valuation

P/E ratio: –
Price to sales: 61.15
Price to book: –
Dividend yield: –